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Introduction
The human ADAMTS family comprises 19 structurally
complex metalloproteinases containing a variable number of
type-1 thrombospondin (TSP-1) domains in the region of their
carboxy-termini (Cal et al., 2002; Llamazares et al., 2003;
Porter et al., 2005). Functional studies have demonstrated the
participation of these enzymes in a variety of processes, such
as collagen maturation, organogenesis, proteoglycan
degradation, inhibition of angiogenesis, reproduction and
inflammation. Furthermore, deficiency or overexpression of
specific ADAMTS proteins is directly involved in serious
human diseases. Human ADAMTS proteins can be classified
into seven subfamilies in accord with their structural and
biochemical features. Notably, ADAMTS1, ADAMTS4,
ADAMTS5, ADAMTS8 and ADAMTS9 are able to cleave
cartilage aggrecan and can contribute to cartilage degradation
in osteoarthritic diseases (Porter et al., 2005). In particular,
ADAMTS5 is now considered to be the major functional
aggrecanase because mice deficient in this enzyme show a
marked reduction in the severity of cartilage destruction in
comparison with wild-type mice (Glasson et al., 2005; Stanton
et al., 2005). ADAMTS2, ADAMTS3 and ADAMTS14 are
aminoprocollagen peptidases (Colige et al., 2005; Colige et al.,
2002; Wang et al., 2003), and ADAMTS2 deficiency causes
Ehlers-Danlos syndrome VIIc in humans and dermatosparaxis
in animals, a disease characterized by a decrease in the tensile
strength and integrity of the skin, joints and other connective
tissues (Colige et al., 1999). ADAMTS13 is the proteinase
responsible for cleaving von Willebrand factor, and mutations
in the ADAMTS13 gene cause a severe blood disease named
thrombotic thrombocytopenic purpura (Levy et al., 2001).
ADAMTS9 (Clark et al., 2000; Somerville et al., 2003) and
ADAMTS20 (Llamazares et al., 2003; Somerville et al., 2003)
are named the GON-ADAMTS proteins as their gene
sequences show a high degree of sequence similarity with the
Caenorhabditis elegans gon-1 gene, which is essential for
formation of gonads (Blelloch et al., 1999). Mutations in
ADAMTS10 cause an autosomal recessive disorder of
connective tissue called Weill-Marchesani syndrome
(Dagoneau et al., 2004). ADAMTS1 and ADAMTS8 are
potent angio-inhibitory enzymes (Vazquez et al., 1999), and
Adamts1-deficient mice display altered morphology and
function of organs and reduced fertility (Shindo et al., 2000).
It is remarkable that certain members of this metalloproteinase
family are dysregulated in tumours of varying origins. These
include ADAMTS6 and ADAMTS18 in breast cancer (Porter
et al., 2004), ADAMTS19 in osteosarcoma (Cal et al., 2002),
ADAMTS20 in breast and colon carcinomas (Llamazares et
Members of the ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motifs) family of
proteolytic enzymes are implicated in a variety of
physiological processes, such as collagen maturation,
organogenesis, angiogenesis, reproduction and
inflammation. Moreover, deficiency or overexpression of
certain ADAMTS proteins is directly involved in serious
human diseases, including cancer. However, the functional
roles of other family members, such as ADAMTS12,
remain unknown. Here, by using different in vitro and in
vivo approaches, we have evaluated the possible role of
ADAMTS12 in the development and progression of cancer.
First, we show that expression of ADAMTS12 in Madin-
Darby canine kidney (MDCK) cells prevents the
tumorigenic effects of hepatocyte growth factor (HGF) by
blocking the activation of the Ras-MAPK signalling
pathway and that this regulation involves the
thrombospondin domains of the metalloproteinase. We also
show that addition of recombinant human ADAMTS12 to
bovine aortic endothelial cells (BAE-1 cells) abolishes their
ability to form tubules upon stimulation with vascular
endothelial growth factor (VEGF). Additionally, tumours
induced in immunodeficient SCID mice injected with A549
cells overexpressing ADAMTS12 show a remarkable
growth deficiency in comparison with tumours formed in
animals injected with parental A549 cells. Overall, our data
suggest that ADAMTS12 confers tumour-protective
functions upon cells that produce this proteolytic enzyme.
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al., 2003) and ADAMTS4 and ADAMTS5 in glioblastomas
(Held-Feindt et al., 2006).
Despite significant advances in our understanding of the
biological functions of some of these enzymes, the roles of
other family members, such as ADAMTS12, remain unknown.
The ADAMTS12 metalloproteinase was originally identified
and cloned in our laboratory by using human foetal lung cDNA
samples (Cal et al., 2001) and has been proposed to participate
in the initiation and progression of arthritis through its ability
to degrade cartilage oligomeric matrix protein (Kevorkian et
al., 2004; Liu et al., 2006). However, at present, no data are
available concerning a putative role for ADAMTS12 in the
development and progression of cancer. To this end, we have
analyzed the effects of the exogenous expression of
ADAMTS12 in MDCK cells. This cell line constitutes a good
model system to study changes in cellular phenotype because
it undergoes striking morphological changes, from cobblestone
to long-spindle shapes, following HGF treatment, an effect
known as ‘scattering’ (Weidner et al., 1990). Moreover, MDCK
cells grown in 3D collagen gels form cyst structures, and HGF
stimulation induces tubulogenesis (O’Brien et al., 2002), a
phenotype relevant to renal development and carcinogenesis.
Early in tubule development, cells form long invasive
extensions that represent a partial epithelial-mesenchymal
transition (EMT) (O’Brien et al., 2004). The morphological
changes that accompany the EMT occur through activation of
Met, the HGF receptor, switching on a complex signalling
pathway that finally leads to downregulation of E-cadherin,
upregulation of vimentin and secretion of several extracellular
proteinases that are essential for matrix remodelling
(Birchmeier et al., 2003).
Here, we report that expression of ADAMTS12 in MDCK
cells prevents the tumorigenic effect caused by HGF
stimulation and show that this effect derives from the inhibition
of components of the Ras-MAPK signalling pathway. We also
show that addition of recombinant human ADAMTS12 to
bovine aortic endothelial cells (BAE-1 cells) abolishes their
ability to form tubules upon stimulation with VEGF. Finally,
we report that tumours induced in immunodeficient mice
injected with A549 cells overexpressing ADAMTS12 exhibit
a marked growth deficiency in comparison with tumours
formed in mice injected with control A549 cells. Overall, our
data indicate that ADAMTS12 could act as an angio-inhibitory
proteinase with the ability to confer anti-tumorigenic
properties to epithelial or endothelial cells.
Results
Generation of stable MDCK clones expressing
ADAMTS12
MDCK cells were transfected with the full-length cDNA for
ADAMTS12 (Fig. 1A), and the expression of the recombinant
protein in the stable clones was examined by both RT-PCR and
western blot analysis (Fig. 1B). These analyses allowed us to
detect the expression of ADAMTS12 in MDCK clones TS12-
4 and TS12-22. A specific band of molecular mass ~175 kDa
was visualized by western blot using antibodies against
ADAMTS12 and the FLAG epitope (Fig. 1B, and data not
shown). Additionally, immunocytochemical analysis of these
clones with the antibody against FLAG allowed the
ADAMTS12 protein to be localized on the cell surface (Fig.
1C). Likewise, and consistent with previous studies (Cal et al.,
2001), the entire protein was not detected in the cell medium.
The MDCK clone stably transfected with the empty pCEP
vector (cMDCK) did not show immunoreactivity for the
antibodies against both ADAMTS12 and FLAG in these
assays, and it was subsequently used as a negative control.
Clones TS12-4 and TS12-22 were chosen for further
evaluation of the putative phenotypic changes accompanying
ADAMTS12 expression in MDCK cells.
MDCK ADAMTS12 clones are refractory to the
scattering effect of HGF treatment
Following HGF stimulation, the scattering effect in MDCK
cells occurs concurrently with the disassembly of junctional
components, which leads to a rapid loss of cell-cell adhesions
(Singh et al., 2004). To evaluate whether these effects were
modified in the selected ADAMTS12-expressing clones,
TS12-4 and TS12-22 clones were cultured in the presence or
absence of HGF (50 ng/ml), and morphological changes were
visualized 16 hours later. The levels of production of
ADAMTS12 and its localization do not seem to be affected by
stimulation with the growth factor (data not shown). As can be
seen in Fig. 2, cMDCK, TS12-4 and TS12-22 clones formed
colonies of similar morphology when cultured in the absence
Fig. 1. Characterization of MDCK ADAMTS12 stable transfectants.
(A) Domain organization of ADAMTS12 showing the position of the
FLAG epitope. (B) RT-PCR and western blot analysis of the
ADAMTS12-expressing clones TS12-4 and TS12-22, using the H-
142 antibody against ADAMTS12. The cMDCK clone was used as a
negative control in these assays. In RT-PCR experiments,
amplification of mRNA encoding -actin was used to ascertain RNA
integrity and ensure equal loading. (C) Immunostaining of non-
permeabilized cMDCK, TS12-4 and TS12-22 cells using an anti-
FLAG antibody. Bar, 10 m.J
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of HGF. However, following HGF treatment, the cMDCK
clone showed the long spindle-shape morphology and reduced
cell-cell adhesion characteristic of epithelial cells treated with
this growth factor. By contrast, TS12-4 and TS12-22 clones
were clearly refractory to HGF stimulation as the cells
remained in contact with each other and formed epithelial-like
colonies, and the scattering could only be occasionally
observed in some cells surrounding the colonies. Likewise, we
also assayed a MDCK clone that expresses an ADAMTS12
form containing changes in two key amino acids in the catalytic
domain, resulting in an enzymatically inactive enzyme (Cal et
al., 2001). Detection of this mutant ADAMTS12 was
performed as described for TS12-4 and TS12-22 clones (data
not shown). Fig. 2 illustrates that this clone, TS12-MUT, was
also refractory to the morphological changes that are expected
upon HGF stimulation. This observation, together with the lack
of effect of the broad-range metalloproteinase inhibitor
ilomastat on the HGF-stimulated TS12-4 and TS12-22 clones
(data not shown), suggests that the described effects are not
caused by the catalytic domain of the enzyme. Moreover, no
changes were observed in the proliferation rates of the selected
clones, indicating that ADAMTS12 expression in MDCK cells
counteracts the HGF-mediated effects on cell-cell contacts and
motility.
Journal of Cell Science 120 (20)
ADAMTS12 negatively regulates the HGF signalling
pathway
HGF induces cell proliferation and migration through its
tyrosine kinase receptor Met (Zhang and Vande Woude, 2003).
We asked whether the inhibition of the scattering effect
observed in MDCK cells transfected with ADAMTS12 could
occur through this metalloproteinase exerting a negative
regulatory signal upon the HGF pathway. To address this
question, we prepared whole-cell extracts from both growth-
factor-treated MDCK clones and untreated control clones, and
levels of different components of the HGF pathway were
evaluated by western blot. The results shown in Fig. 3A
revealed that, in the absence of HGF stimulation, there were
no differences in the levels of E-cadherin, vimentin, ERK,
phosphorylated ERK (P-ERK), AKT, phosphorylated (P-
AKT) and phosphorylated Met (P-Met) among the three clones
analyzed, cMDCK, TS12-4 and TS12-22. Likewise, we have
found that the expression of the metalloproteinase did not
increase the ectodomain shedding of Met. By contrast, clear
differences in the levels of some of the analyzed proteins were
apparent when cells were stimulated with the growth factor (+
Fig. 2. MDCK ADAMTS12-expressing clones are refractory to the
scattering effect of HGF stimulation. The control cMDCK clone
shows reduced cell-cell adhesion and has a spindle-shape
morphology upon treatment with HGF. By contrast, TS12-4 and
TS12-22 still form epithelial-like colonies after 16 hours of
incubation with HGF. A MDCK clone that expresses a catalytically
inactive mutant version of ADAMTS12 (TS12-MUT) is also
refractory to the scattering effect. Bar, 50 m.
Fig. 3. ADAMTS12 negatively regulates the HGF signalling
pathway. (A) Levels of different components of the HGF pathway
(E-cadherin, vimentin, ERK, P-ERK, AKT, P-AKT and P-Met) were
evaluated by western blot in the selected cMDCK, TS12-4 and TS12-
22 clones, in both non-stimulated (– HGF) and stimulated (+ HGF)
conditions. Ectodomain shedding of Met was also analyzed in the
conditioned medium from these clones (Met). (B) Immunostaining of
E-cadherin and vimentin in the selected clones without (– HGF) and
with (+ HGF) stimulation by hepatocyte growth factor. Bar, 10 m.
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HGF, Fig. 3A). Thus, E-cadherin expression was clearly
diminished in the cMDCK control clone upon HGF
stimulation, whereas, in the ADAMTS12 clones, its expression
was similar in both stimulated and non-stimulated cells. In
addition, the cMDCK clone produced high levels of vimentin
upon HGF stimulation, a change that was not observed in the
TS12-4 and TS12-22 clones. Similarly, the levels of the active
phosphorylated form of ERK (P-ERK) were significantly
lower in the clones that expressed ADAMTS12 than in the
corresponding controls following HGF treatment. Finally, we
also observed that the levels of both AKT and phosphorylated
AKT were similar among the analyzed clones in both
stimulated and non-stimulated samples.
To further evaluate the observed differences between
ADAMTS12-producing clones and control cells, we next
performed an immunocytochemical analysis of E-cadherin and
vimentin expression in these cells, both in the presence and
absence of HGF. As can be seen in Fig. 3B, and in agreement
with the results obtained by western blot analysis, cell-surface
staining for E-cadherin was clearly detected in TS12-4 and
TS12-22 clones, in both stimulated and non-stimulated
samples, but negligible or no staining was observed for
vimentin. By contrast, the response of cMDCK control cells to
HGF stimulation was characteristic of an EMT as vimentin was
clearly visible in HGF-treated cells and as E-cadherin levels
were virtually undetectable following treatment with the
growth factor (Fig. 3B). These results lead us to conclude that
expression of ADAMTS12 can negatively regulate the HGF
signal-transduction pathway. Moreover, the lowered levels of
P-ERK detected in the ADAMTS12-expressing MDCK cells
when compared with control MDCK cells suggest that the
effects mediated by this metalloproteinase arise from an
inhibition of the Ras-MAPK cascade and are independent of
Met activation.
MDCK clones expressing ADAMTS12 fail to form tubular
structures in a 3D collagen lattice
HGF mediates tubular morphogenesis in MDCK cells when
grown within 3D collagen networks (Ridley et al., 1995). To
evaluate the possible influence of ADAMTS12 expression on
MDCK tubulogenic properties, TS12-4, TS12-22 and cMDCK
clones were cultured in 3D collagen gels and stimulated with
HGF, as described above. As a positive control for this
experiment, we used a MDCK clone (MT1-MDCK) that
expresses MT1-MMP, a membrane metalloproteinase that
induces morphological changes to generate large cavities in the
collagen gel (Hotary et al., 2000; Kadono et al., 1998). As can
be seen in Fig. 4, MDCK cells that express ADAMTS12 form
cysts when cultured in the presence of HGF in 3D collagen
gels. However, these clones develop neither any tubular
structures nor even any spiking or scattering of the cells that
could indicate an early EMT (O’Brien et al., 2004). By
contrast, morphological changes were observed in both
cMDCK and MT1-MDCK clones. Thus, around 30% of the
cysts formed by cMDCK cells, and 41% of those formed by
MT1-MDCK cells, showed long extensions from the edge,
which were clearly detectable after 7 days of incubation. By
contrast, less than 10% of the cysts formed by TS12-4 and
TS12-22 clones showed extensions, and such extensions were
considerably shorter than those formed by the cMDCK and
MT1-MDCK clones. These proportions were maintained when
the tubule formation was followed for a longer period (data not
shown). These findings indicate that ADAMTS12 expression
might affect the ability of MDCK cells to invade a collagen
matrix and constitute additional evidence concerning the
inhibitory effects that this metalloproteinase can cause on the
HGF signal-transduction cascade.
ADAMTS12 lacking thrombospondin domains does not
inhibit EMT in HGF-stimulated MDCK cells
To test whether the thrombospondin domains of ADAMTS12
could be involved in the inhibitory effects observed in the
TS12-4 and TS12-22 clones, we prepared a new clone,
MDCK-TS12, that stably expresses a truncated form of the
protein lacking the TSP-1 domains (Fig. 5A,B). Scattering
analysis, culture in 3D collagen gels and study of vimentin and
E-cadherin expression revealed that this clone does not show
any of the inhibitory effects described for those clones that
express the full-length protein (Fig. 5C). Similar results were
obtained when this assay was performed in the presence of the
metalloproteinase inhibitor ilomastat (data not shown), which
suggests that these effects are not due to the enzymatic activity
of the protein. The two bands detected by western blot analysis
of cell extracts could correspond to the entire protein (top band)
and the mature TS12 (bottom band), once the prodomain is
removed in the trans-Golgi by a furin-like protease. According
to these findings, the metalloproteinase and disintegrin
domains are not sufficient to trigger the effects observed in
the TS12-4 and TS12-22 clones. Hence, the presence of the
angio-inhibitory TSP-1 domains as exosites within the
metalloproteinase structure seems to be required to induce the
negative regulatory effect following HGF stimulation.
Production, purification and enzymatic analysis of
recombinant ADAMTS12
To further examine the relevance of ADAMTS12 in EMT
Fig. 4. MDCK cells expressing ADAMTS12 fail to form tubular
structures in a 3D collagen matrix. Selected clones expressing
ADAMTS12, TS12-4 and TS12-22 were grown within a collagen gel
for seven days. Morphological changes such as long extensions
(arrows) from the cysts are clearly observed in cMDCK and MT1-
MDCK clones. Bar, 50 m.
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processes, we next generated 293-EBNA cells stably
expressing this enzyme (EBNA-TS12), following a strategy
similar to that described above for MDCK cells. It was possible
to recover the metalloproteinase from the membrane-
associated fraction by using a buffer containing 0.5 M NaCl,
suggesting that, after secretion, this proteinase is immobilized
around the pericellular space (Fig. 6A). After purification of
the recombinant ADAMTS12 using an anti-FLAG affinity gel
column, we performed a western blot analysis with an antibody
against FLAG that allowed the detection of the purified
ADAMTS12 (Fig. 6A). The purified enzyme was employed to
test its activity by using aggrecan as a potential substrate. An
Journal of Cell Science 120 (20)
equivalent fraction derived from a 293-EBNA clone stably
transfected with an empty vector was used as a negative control
(c-EBNA), whereas ADAMTS4, a potent aggrecanase, was
used as positive control in this assay. As shown in Fig. 6B,
the isolated recombinant ADAMTS12 displayed a clear
aggrecanase activity, as assessed by western blot analysis using
the BC-3 antibody that detects aggrecan degradation products.
Moreover, this activity is abolished when the enzyme is pre-
incubated with the metalloproteinase inhibitor ilomastat. These
results confirm that recombinant ADAMTS12 produced in
293-EBNA cells is enzymatically active and thereby useful for
the analysis reported below.
Effects of ADAMTS12 on VEGF-induced tubulogenesis
in BAE-1 cells
To analyze whether the exogenous administration of
ADAMTS12 could also affect tubulogenesis in a different
system, we chose the endothelial cell line BAE-1, which forms
capillary networks in collagen lattices when cultured in the
presence of VEGF (Maeshima et al., 2004). In these conditions,
purified ADAMTS12 or the corresponding cell-layer-associated
Fig. 5. Cells expressing a truncated ADAMTS12 lacking
thrombospondin domains (ADAMTS-TS12) undergo an EMT
following HGF stimulation. (A) Domain organization of ADAMTS-
TS12. The position of the HisTag epitope is indicated. (B)
Expression analysis of ADAMTS-TS12 by RT-PCR and western
blot using an antibody against the HisTag. In both cases, the cMDCK
clone was used as a control. Truncated ADAMTS12 is located in the
conditioned medium of cells that stably express this form of the
enzyme. In RT-PCR, amplification of the mRNA encoding -actin
was used to ascertain RNA integrity and ensure equal loading. (C)
Scattering assay (2D), tubulogenesis assay (3D) and immunostaining
of E-cadherin and vimentin of the ADAMTS-TS12-expressing cells
in the absence (– HGF) or presence (+ HGF) of hepatocyte growth
factor. Bars, 30 m (left, centre); 10 m (right).
Fig. 6. Purification process and enzymatic activity of ADAMTS12.
(A) Western blot analysis of ADAMTS12 during the purification
process. c-EBNA and EBNA-TS12 indicate cell-layer-associated
fractions from 293-EBNA cells transfected with an empty vector, and
the equivalent fraction from 293-EBNA cells expressing
ADAMTS12, respectively. Recombinant purified ADAMTS12 is
also indicated. (B) Following incubation of aggrecan with
recombinant ADAMTS4 (lane 2), purified ADAMTS12 (lane 3) or
an equivalent fraction purified from c-EBNA cells (lane 1), samples
were deglycosylated and the aggrecan degradation products were
detected by using the BC-3 antibody. In lane 4, purified ADAMTS12
was previously incubated with the metalloproteinase inhibitor
ilomastat (+Ilo). Molecular mass markers (kDa) in both panels are
indicated on the left.
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fraction from 293-EBNA cells expressing ADAMTS12 were
added to the cell cultures, and tubulogenesis was evaluated 48
hours later. As a negative control, BAE-1 cells under the same
culture conditions were incubated with equivalent fractions of
293-EBNA cells stably transfected with the empty vector. As can
be seen in Fig. 7, BAE-1 cells cultured in the presence of VEGF
formed tubules and ~64% of cell clusters contained capillary
structures. By contrast, formation of these capillary networks
was drastically reduced in the presence of ADAMTS12, and less
than 10% of cell clusters showed any tubular structures. Control
cells, grown either without the recombinant ADAMTS12, or in
the presence of the cell-layer-associated fraction from control
293-EBNA cells, clearly showed tubular morphogenesis in
>40% of the cell clusters. Similar values were obtained when
cells were grown in the presence of the protein lacking the
thrombospondin domains (TS12), which was carried out by
adding to the BAE-1 cells conditioned medium from the MDCK
cells that expressed this truncated form of the enzyme. From
these assays, we conclude that, in this system, ADAMTS12
inhibits the formation of VEGF-induced tubular structures in
BAE-1 cells. It cannot be ruled out that the metalloproteinases
can interact with the growth factor. This situation would
resemble that found for ADAMTS1, in which this
metalloproteinase binds to VEGF through the thrombospondin
domain of its C-terminal region (Luque et al., 2003).
ADAMTS12 inhibits tumour growth in vivo
A549 is a human lung adenocarcinoma cell line that forms
primary tumours when injected into immunodeficient mice (Rao
et al., 2005; Wedge et al., 2002). To evaluate the effect of
ADAMTS12 expression in the in vivo tumour formation assay
by A549 cells, we first selected a stable clone, A549-TS12, that
expresses ADAMTS12. The presence of the metalloproteinase
was determined by RT-PCR, western blot and
immunocytochemistry (data not shown). A549-TS12 cells were
subcutaneously injected in the flank of four SCID mice. Control
parental A549 cells were injected in the same conditions in a
further four animals, and the evolution of tumour growth was
followed for five weeks. As can be seen in Fig. 8A,B, A549-
TS12 cells overexpressing the metalloproteinase display a
significantly reduced tumour growth rate in comparison with
A549-derived tumours. Thus, after 37 days, the average tumour
volume in mice that received the A549-TS12 clone was only
~50% of the tumour volume of mice that received the A549
parental cells. Moreover, in the case of the A549-TS12 clone,
the tumours were macroscopically visible four weeks after cells
injection, whereas the tumours produced by the parental A549
cells could already be detected by three weeks after injection.
These results indicate that ADAMTS12 might also confer anti-
tumour properties in vivo.
Fig. 7. Effect of ADAMTS12 on tubulogenesis of BAE-1 cells.
BAE-1 cells were cultured within a collagen gel for 2 days in the
absence (a) or presence (b–f) of 100 ng/ml VEGF. 10 l of the cell-
layer-associated fraction from 293-EBNA cells that express
ADAMTS12 (EBNA-TS12) (c), or the same amount of the
equivalent fraction from c-EBNA cells (d), were added to the culture.
BAE-1 cells were grown in the presence of 10 l of purified
ADAMTS12 (e), or the same amount of the equivalent fraction
purified from c-EBNA cells (f). Addition of 50 l of conditioned
medium from cells that express truncated ADAMTS12 (g) or from
control cells transfected with an empty vector (h) does not affect the
ability of BAE-1 cells to form a capillary network in the presence of
VEGF. Bar, 30 m.
Fig. 8. Inhibition of subcutaneous tumour growth by ADAMTS12.
(A) SCID mice were injected with parental A549 cells or with cells
from an A549 clone (A549-TS12) expressing ADAMTS12. Tumour
growth was followed until day 37, and tumour volumes were
calculated after measurements were taken with a calliper. (B)
Representative subcutaneous tumours at day 37 following injection
are shown for mice that received A549 or A549-TS12 cells
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Discussion
ADAMTS12 is a complex metalloproteinase that contains
multiple TSP-1 repeats in its C-terminal region and whose
expression has been detected mainly in some human foetal
tissues as well as in a variety of carcinomas and cancer cell
lines (Cal et al., 2001). As a first step to study the putative
functional relevance of ADAMTS12 in tumour-associated
processes, we have analyzed in this work whether the
expression of this proteinase could affect the morphological
changes that MDCK cells undergo following HGF treatment.
This cellular model has been successfully used to evaluate how
different members of the matrix metalloproteinase (MMP)
family promote the generation of an invasive phenotype in
MDCK cells engineered to overproduce these enzymes (Hotary
et al., 2000; Kadono et al., 1998; Kang et al., 2000). Following
a similar strategy, and after selection of two MDCK clones that
expressed ADAMTS12, we first observed that these clones
were very refractory towards undergoing the scattering effect
characteristic of MDCK cells upon HGF stimulation. Likewise,
within collagen gels, the ADAMTS12-producing cells could
form cysts, but neither tubules nor other morphological
alterations such as spindle-shaped extensions were observed on
the surface of the cysts. Western blot and immunocytochemical
analysis showed that HGF stimulation did not downregulate E-
cadherin or upregulate vimentin expression in the
ADAMTS12-expressing clones, as would otherwise be
expected for MDCK cells treated with this growth factor
(Bolos et al., 2003).
Analysis of the putative signalling pathways underlying the
observed effects induced by ADAMTS12 expression
implicated the Ras-MAPK pathway in these events, as deduced
from the fact that levels of active phosphorylated ERK were
diminished in the ADAMTS12-expressing clones compared
with control cells. This signalling cascade is involved in the
regulation of epithelial tubule development in MDCK cells
(O’Brien et al., 2004) and is necessary and sufficient to initiate
tubulogenesis (Hellman et al., 2005). Moreover, sustained
activation of ERK seems to be crucial for cell scattering (Liang
and Chen, 2001). Our data are consistent with the possibility
that ADAMTS12 inhibits the cellular processes that regulate
the EMT in HGF-stimulated MDCK cells.
How could ADAMTS12 mediate these effects? The above
results were obtained by using MDCK clones that expressed
the entire metalloproteinase. However, after performing the
same assays with cells producing a mutant ADAMTS12
protein lacking the thrombospondin domains, we observed that
this truncated enzyme was unable to inhibit the effects induced
by HGF, thereby suggesting that the C-terminal TSP-1
domains of ADAMTS12 might regulate this process.
Moreover, MDCK cells that expressed a catalytically inactive
ADAMTS12 form were also refractory to the scattering effect.
Consistent with this proposal, inhibition of endothelial cell
migration by TSP-1 occurs through the interaction with its
receptor CD36, and cellular levels of TSP-1 are regulated by
tumour-suppressor genes and oncogenes (Ren et al., 2006). It
has also been reported that HGF turns off TSP-1 expression in
MDCK cells to avoid negative regulatory signals on cell
proliferation and migration and that this downregulation
depends on the MAPK pathway and operates independently of
the phosphoinositide 3-kinase and Stat3 pathways (Zhang and
Vande Woude, 2003). Furthermore, and in relation to the
Journal of Cell Science 120 (20)
possibility that other ADAMTS proteins could play similar
roles, it has been reported recently that ADAMTS1 from
Xenopus also negatively modulates the Ras-MAPK pathway
through inhibition of ERK phosphorylation and that the C-
terminal region of the protein containing the TSP-1 domains is
necessary and sufficient for this function (Suga et al., 2006).
Interestingly, both ADAMTS1 and ADAMTS12 are enzymes
that undergo several proteolytic processing events to generate
several fragments that might play different roles (Cal et al.,
2001; Rodriguez-Manzaneque et al., 2000). The balance
between the various generated fragments could influence the
pro- or anti-metastatic activities of ADAMTS12, as has been
shown for ADAMTS1 (Liu et al., 2006; Masui et al., 2001).
To evaluate the potential anti-tumorigenic effects of
ADAMTS12 in vivo, we analyzed the growth of the poorly
differentiated non-small-cell lung cancer cell line A549,
engineered to produce ADAMTS12, in immunodeficient SCID
mice. The A549 parental cell line has been used previously
to determine that downregulation of the MMP-9
metalloproteinase has a significant inhibitory effect on tumour
growth and progression (Rao et al., 2005). Conversely, we
observed that A549 cells expressing ADAMTS12 form
subcutaneous tumours in SCID mice, but the tumour volumes
were considerably smaller than those produced by parental
A549 cells. This observation suggests that ADAMTS12
expression might delay tumour growth, which agrees with our
in vitro findings on the potential anti-tumour effects of this
metalloproteinase. These results, based on using an animal
model, open the possibility for future work aimed at evaluating
the regulatory roles of ADAMTS12 in other in vivo tumour-
associated processes such as angiogenesis or metastasis.
In conclusion, the results presented in this work suggest that
ADAMTS12 could confer tumour-protective functions. In
agreement with this idea, it has been recently established that
Ki-Ras-transformed mouse colonocytes expressing high levels
of Myc promote the formation of highly vascularized tumours.
This effect is due, at least in part, to the downregulation of a
series of angio-inhibitory proteins, including ADAMTS12
(Dews et al., 2006). The finding of anti-tumorigenic effects for
a metalloproteinase is not unprecedented as it has also been
described for other enzymes of this catalytic class, including
several MMPs (Acuff et al., 2006; Balbin et al., 2003;
Folgueras et al., 2004; Houghton et al., 2006). These findings
point to the occurrence of alternative proteinase functions in
cancer and also reinforce the need for analyzing the tumour
‘degradome’ – the entire set of proteinases produced by a
specific tumour in a certain stage of development (Lopez-Otin
and Overall, 2002). These proteinase-profiling approaches
might also contribute to the identification of therapeutic targets
for the future design of specific inhibitors that would block
only the unwanted activity of these enzymes during tumour
progression (Overall and Lopez-Otin, 2002). Generation of
mice lacking ADAMTS12, now in progress, will provide an
essential tool to understand better the relevance of this enzyme
in tumour-associated processes.
Materials and Methods
Cell culture, transfection and cDNA constructs
MDCK, 293-EBNA, A549 and BAE-1 cells were routinely maintained in DMEM
medium containing 10% heat-inactivated foetal bovine serum and 100 U/ml
penicillin and 50 g/ml streptomycin. Full-length cDNA encoding ADAMTS12
was amplified by PCR from the vector pcDNA3-ADAMTS12-HA (Cal et al., 2001),
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and it was cloned between the HindIII and NotI sites of a modified pCEP4
expression vector (Life Technologies). Additionally, two oligonucleotides (5-
GGCCGACTACAAGGACGACGATGACAAG-3 and 5-GGCCCTTGTCAT -
CGT CGTCCTTGTAGTC-3) were used to introduce a FLAG epitope at the NotI
site. The generated plasmid, pCEP-TS12, was transfected into MDCK and 293-
EBNA cells using the lipofectamine reagent (Life Technologies), as recommended
by the manufacturer. MDCK and 293-EBNA clones stably expressing ADAMTS12
or transfected with the empty vector to be used as a negative control were selected
in the presence of 2 g/ml puromycin (Sigma-Aldrich). When indicated, a MDCK
clone expressing a mutant ADAMTS12 (TS-12 MUT) was employed. This form of
ADAMTS12 contains two mutations in the metalloproteinase domain to produce a
catalytically inactive enzyme (Cal et al., 2001). MT1-MMP cDNA was a generous
gift from M. Seiki (Institute for Medical Science, University of Tokyo, Japan) and
was employed to generate MDCK cells that stably expressed this proteinase. MDCK
cells were also transfected with a cDNA encoding a truncated form of ADAMTS12
with a premature stop codon between the Cys-rich and the first TSP-1 domains
(MDCK-TS12). A His-tag tail was added to the C-terminus of this protein to
facilitate its detection by western blot. To detect this truncated form of ADAMTS12,
300 l of the conditioned medium was precipitated with an equal volume of chilled
acetone.
Western blotting
For western blot analysis, the proteins were resolved by 8 or 12% SDS-
polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and
subsequently probed with the indicated antibodies, as recommended by the
manufacturers. The primary antibodies used for detection of specific proteins were
anti-FLAG-M2 (Sigma-Aldrich), H-142 (anti-ADAMTS12; Santa Cruz Biotech),
anti-p44/42 mitogen-activated protein kinase (MAPK), anti-phospho-Akt (Ser473)
and anti-Akt (Cell Signalling Technology); anti-ERK, BC-3, anti-VEGF and anti-
vimentin (Abcam); anti-E-cadherin (kindly supplied by A. Cano, IIB, Madrid,
Spain); anti-MT1-MMP (kindly supplied by A. G. Arroyo, CNIC, Madrid, Spain);
and anti-HisTag (GE Healthcare). Anti-P-Met antibody was from Biosource
International (Camarillo, CA) and anti- Met antibody (clon DL-21) was from
Upstate (Charlottesville, VA). Immunoreactive proteins were visualized using HRP-
peroxidase-labelled anti-rabbit or anti-mouse secondary antibody and the ECL
detection system (Pierce).
Reverse transcription-PCR amplification (RT-PCR)
When indicated, presence of ADAMTS12 in the selected clones was assayed by
RT-PCR. Total RNA from these clones was isolated by guanidium thiocyanate-
phenol-chloroform extraction, and the cDNA synthesis was carried out using the
RNA PCR kit from Perkin-Elmer Life Sciences, as specified by the manufacturer.
After reverse transcription using 1 g of total RNA and random hexamers as
primers, PCR was performed with two specific ADAMTS12 oligonucleotides, (5-
TCACGACGTGGCTGTCCTTCT-3 and 5-ACCACAG TGTCTGGCAGACGT-
3), corresponding to the metalloproteinase domain. cDNA quality was verified by
control RT-PCR reactions using primers derived from the sequence of -actin.
Immunocytochemical analysis
MDCK cells stably expressing ADAMTS12, or control cells carrying an empty
vector, were fixed with 4% paraformaldehyde in phosphate-buffered saline. The
non-permeabilized cells were blocked with 15% foetal bovine serum in the same
buffer. To detect recombinant ADAMTS12, blocked slides were incubated for 2
hours with the primary antibody against FLAG, followed by 2 hours of incubation
with a secondary fluorescein-conjugated sheep anti-mouse antibody (GE
Healthcare). Detection of E-cadherin and vimentin was carried out basically as
described above except that cells were permeabilized with 0.5% Triton X-100 for
5 minutes before adding the primary antibodies. Secondary antibodies were
conjugated with Cy3 and Cy2 (Jackson ImmunoResearch Laboratories),
respectively. In all samples, 4,6-diamino-2-phenylindole hydrochloride (DAPI)
was added at 100 ng/ml to visualize DNA in the cell nucleus. Images were obtained
using fluorescence microscopy and a digital camera.
Production and purification of recombinant ADAMTS12
Production and purification of recombinant ADAMTS12 was performed as
described by Colige et al. (Colige et al., 2002) for ADAMTS14, with some
modifications. In brief, 293-EBNA cells expressing ADAMTS12 (EBNA-TS12)
were scraped from the culture plate, suspended in a buffer containing 50 mM Tris-
HCl, pH 7.4, and 500 mM NaCl and rotated for 2 hours at 4°C. After centrifugation,
the supernatant (cell-layer-associated fraction) was diluted 1:1 (v/v) in the same
buffer lacking NaCl, and loaded onto an anti-FLAG affinity gel column (Sigma-
Aldrich). Elution was carried out by using a FLAG peptide (Sigma-Aldrich), as
recommended by the manufacturer. The purification process was followed by
western blot using the anti-FLAG-M2 antibody. The same process was applied to
an EBNA clone stably transfected with an empty vector.
Enzyme activity assays
The proteolytic activity of recombinant ADAMTS12 was assessed using aggrecan
as a potential substrate. To do this, recombinant purified protein was incubated with
500 nM aggrecan from bovine articular cartilage (Sigma-Aldrich) in a buffer
containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl and 10 mM CaCl2 at 37°C for
16 hours. Next, fragments were enzymatically de-glycosylated using aggrecan
chondroitinase ABC (0.1 U per 10 g of aggrecan; Sigma-Aldrich) at 37°C for 1
hour, followed by 2 hours incubation at 37°C with 0.002 U per 10 g aggrecan of
endo--galactosidase (Sigma-Aldrich). Reaction products were analyzed by
western blot by using the BC-3 antibody. When indicated, the broad-range inhibitor
of metalloproteinases ilomastat (Calbiochem) was employed (5 M final
concentration). As a positive control, aggrecan digestion was carried out by
ADAMTS4 (Chemicon International) under the same experimental conditions.
Scattering assay
Selected MDCK cell clones were seeded in quadruplicate in a 24-well tissue-culture
plate (1104 cells) and were allowed to attach for 6 hours. Next, 50 ng/ml HGF
(R&D Systems) was added to two samples of each quadruplicate and pictures were
taken after 16 hours of incubation, using a video camera attached to a Zeiss Axiovert
200 M motorized inverted microscope.
Tubulogenesis in 3-D collagen gels
Tubulogenesis assays were carried out using a 3D collagen cell culture system
(Chemicon International), following the manufacturer’s instructions. Briefly,
selected MDCK clones (1.5103 cells) were mixed with 200 l of chilled collagen
and allowed to gel at 37°C in 24-well plates. Next, DMEM medium containing 3%
bovine foetal serum and 30 ng/ml HGF was added to the wells. This medium was
renewed every 2-3 days and photographs were taken after 7 days, and the percentage
of cysts with extensions was quantified using a 40 objective on an inverted
microscope (Axiovert 200, Carl Zeiss). In the case of BAE-1 cells, tubule formation
was induced by adding 100 ng/ml VEGF to 5103 cells per well growing in the
collagen gel, and photographs were taken after 2 days, as described by Maeshima
et al. (Maeshima et al., 2004). To semi-quantify tubulogenic activity, the percentage
of cell clusters containing tubular structures was determined. When indicated,
different amounts of recombinant ADAMTS12 directly extracted from the 293-
EBNA cell layer or after purification were added to the wells.
Animals and subcutaneous tumours
Male adult severe combined immunodeficient mice (SCID; C.B-17/IcrCrl-scid-BR)
were obtained from Charles River Laboratories (Sulzfeld, Germany), and animal
care and experimentation was carried out following institutional guidelines
approved by the local animal review board. Mice were kept in sterile cages bedded
with sterilized soft wood granulate and fed irradiated rat chow ad libitum with
autoclaved water in a 12-hour light-dark cycle. All manipulations were performed
in a laminar-flow hood and the mice were intraperitoneally anaesthetized with a
mixture of 50 mg/kg ketamine and 10 mg/kg xylazine. For euthanasia, animals were
given a lethal dose of ketamine and xylazine. To induce subcutaneous tumours,
suspensions of A549 cells or A549 that expressed recombinant ADAMTS12 (A549-
TS12) were subcutaneously injected (6106 cells in 0.5 ml PBS) into the left side
of four SCID mice. Selection of the clone A549-TS12 was carried out following a
procedure similar to that described above for the generation of stable ADAMTS12-
expressing MDCK and 293-EBNA cells. The health status of mice and appearance
of tumours was monitored routinely and the animals remained healthy throughout
the entire experiment. Tumour size was measured with a calliper and tumour volume
was determined using the formula: V=0.4 AB2, where A is the largest dimension
of the tumour and B is the smallest dimension.
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